EXTENDED INDUCTION IN THE TRUE NORTH OPEN-LABEL EXTENSION STUDY: CLINICAL OUTCOMES OF ∼2 YEARS OF OZANIMOD TREATMENT

被引：0
|
作者：
Rubin, David T.
Colombel, Jean Frederic
Chiorean, Michael V.
Ghosh, Subrata
Jain, Anjali
Lawlor, Garrett
Osterman, Mark T.
Wu, Hsiuanlin
Canavan, James B.
Vermeire, Severine
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1736
引用
收藏
页码：S1102 / S1102
页数：1
相关论文
共 50 条
  • [41] Absolute Lymphocyte Count Around Infections During Phase 3 and Open-Label Extension Trials of Ozanimod in Participants With Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Hartung, Hans-Peter
    Steinman, Lawrence
    Bar-Or, Amit
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Harris, Sarah
    Reardon, Jennifer
    Thorpe, Andrew
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1016 - 1017
  • [42] Extended release carbamazepine in the treatment of pathological gambling: An open-label study
    Black, Donald W.
    Shaw, Martha C.
    Allen, Jeff
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2008, 32 (05): : 1191 - 1194
  • [43] Safety Patterns Over up to 8 Years With Ozanimod in Patients with Relapsing Multiple Sclerosis: Final Results From the DAYBREAK Open-label Extension Study
    Selmaj, Krzysztof
    Ziemssen, Tjalf
    Comi, Giancarlo
    Hartung, Hans-Peter
    Sheffield, James
    Cheng, Chun-Yen
    Riolo, Jon
    Thorpe, Andrew
    Krakovich, Anthony
    Singal, Mohini
    Vermersch, Patrick
    Cree, Bruce A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1019 - 1020
  • [44] Correlations Between Early MRI Parameters and Long-term Clinical Outcomes in Phase 3 and Open-label Extension Studies of Ozanimod in Relapsing Multiple Sclerosis
    Arnold, Douglas L.
    Freeman, Leorah
    Hartung, Hans-Peter
    Montalban, Xavier
    Cohen, Jeffrey A.
    Bar-Or, Amit
    Steinman, Lawrence
    DeLuca, John
    Cheng, Chun-Yen
    Riolo, Jon V.
    Silva, Diego
    Pachai, Chahin
    Cree, Bruce A. C.
    NEUROLOGY, 2023, 100 (17)
  • [45] Long-term treatment with zonisamide: Results of a 2 year open-label extension study
    Wroe, S.
    Duncan, R.
    EPILEPSIA, 2006, 47 : 138 - 138
  • [46] Correlations between early MRI parameters and long-term clinical outcomes in phase 3 and open-label extension studies of ozanimod in relapsing multiple sclerosis
    Arnold, D. L.
    Freeman, L.
    Hartung, H. -P.
    Xavier Montalban, X.
    Cohen, J. A.
    Bar-Or, A.
    Steinman, L.
    DeLuca, J.
    Cheng, C. -Y.
    Riolo, J. V.
    Silva, D.
    Pachai, C.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 377 - 378
  • [47] An open-label clinical study of nitazoxanide in the treatment of human fascioliasis
    Kabil, SM
    El Ashry, E
    Ashraf, NK
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2000, 61 (06): : 339 - 345
  • [48] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis in daybreak: an open-label extension study of ozanimod phase 1-3 trials
    Selmaj, K.
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Arnold, D.
    Hartung, H. P.
    Montalban, X.
    Havrdova, E.
    Sheffield, J.
    Chen, T.
    Minton, N.
    Silva, D.
    Kappos, L.
    Cohen, J.
    Cree, B.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 223 - 223
  • [49] OPEN-LABEL EXTENSION STUDY: TEZACAFTOR/IVACAFTOR, PATIENTS ≥ 12 YEARS WITH CYSTIC FIBROSIS
    Wainwright, C.
    Flume, P.
    Biner, Fischer R.
    Downey, D.
    Brown, C.
    Jain, M.
    Fischer, R.
    De Boeck, K.
    Campbell, D.
    Wang, X.
    Ahluwalia, N.
    Owen, C.
    RESPIROLOGY, 2020, 25 : 57 - 57
  • [50] Renal outcomes with up to 9 years of migalastat in patients with Fabry disease: Results from an open-label extension study
    Nicholls, Kathleen
    Giugliani, Roberto
    Schiffmann, Raphael
    Hughes, Derralynn A.
    Jain, Vipul
    Holdbrook, Fred
    Skuban, Nina
    Castelli, Jeffery P.
    Barth, Jay A.
    MOLECULAR GENETICS AND METABOLISM, 2018, 123 (02) : S105 - S106
12345